Business Context and Reporting Period
Enanta Pharmaceuticals, Inc. filed a Form 8-K Current Report on January 30, 2014, regarding the appointment of a senior executive. The company is a biotechnology firm incorporated in Delaware with principal offices in Watertown, Massachusetts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Timothy D. Ocain, Ph.D., as Senior Vice President, New Product Strategy and Development, effective January 30, 2014. Dr. Ocain joins from a role as an independent biotechnology consultant and previously held senior positions at Seaside Therapeutics and Millennium Pharmaceuticals.
Compensation and Employment Terms
- Base Salary: $300,000 per year.
- Performance Bonus: Eligible for up to 30% of base salary.
- Equity Grant: Stock option for 70,000 shares (25% vesting after one year; remainder in quarterly installments).
- Signing Bonus: $70,000.
- Relocation Benefits: Up to $26,100 for temporary living/travel expenses and up to $33,550 for moving and closing costs.
- Severance: Agreement includes standard severance terms for termination without cause or following a change in control, consistent with other executive officers.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 70,000 stock options granted to Dr. Ocain.
- Review the specific terms of the employment agreement filed as Exhibit 10.17 to the Form S-1/A (March 5, 2013) for detailed severance conditions.
- Confirm the impact of this appointment on the company's cash burn rate given the immediate cash outlays for signing and relocation bonuses.